Position of the Transparency Council – Kyprolis (carfilzomib)
At its meeting on 6 February 2023, the Transparency Council adopted opinion No. 14/2023 on the evaluation of the medicine Kyprolis (carfilzomib) under the drug programme “Treatment of patients with plasmocytic myeloma (ICD- 10: C90.0)”.